scholarly journals Motives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users

2019 ◽  
Vol 46 (3) ◽  
pp. 304-320 ◽  
Author(s):  
Hannes Kettner ◽  
Natasha L. Mason ◽  
Kim P. C. Kuypers

Novel psychoactive substances (NPS) are compounds designed to mimic the effects of existing recreational drugs (classical psychoactive substances [CPS]), while eluding established legal frameworks. Little is known about their effects and potential harms, rendering the increasing number of NPS a challenge to policy makers and researchers alike. Quantitative studies on the motives underlying NPS use are limited, though understanding them is crucial for the design of effective harm prevention strategies. The present study therefore aimed to compare motivational patterns for NPS, CPS, and legal psychoactive substance (LPS) use. An online survey including questions about lifetime drug use, demographics, and motives for use was completed by 2,319 participants of which 1,967 consented and were 18 years or older. Data on lifetime use and endorsed motives are presented for 12 psychoactive substances classified into LPS (alcohol, nicotine), CPS (cannabis, MDMA/ecstasy, amphetamines, cocaine, psilocybin, LSD, ayahuasca), and NPS (synthetic cannabinoids, stimulant, and hallucinogenic) and compared between classes. Across substances, the most frequently endorsed motives were to feel euphoric (58.0%), enhance an activity (52.3%), and broaden consciousness (48.1%). Motives for use were found to differ by substance and gender, with coping-related reasons being more frequent among female participants compared to males who indicated to use for a broad range of reasons. Motivational patterns of CPS and NPS use were largely similar to their classical analogues, this was not the case for synthetic cannabinoids, which had as main endorsed motive getting intoxicated, indiscriminate of specific qualities. This information can feed into tailoring of educational campaigns and prevention strategies.

2017 ◽  
Vol 41 (S1) ◽  
pp. S311-S311
Author(s):  
M. Lupi ◽  
T. Acciavatti ◽  
S. Marini ◽  
E. Cinosi ◽  
R. Santacroce ◽  
...  

IntroductionComorbidities between psychiatric diseases and consumption of traditional substances of abuse are common. Nevertheless, there is no data regarding the use of novel psychoactive substances (NPS) in the psychiatric population.ObjectivesThe purpose of this multicentre survey is to investigate the consumption of a wide variety of psychoactive substances in a young psychiatric sample.MethodsBetween September 2013 and November 2015, a questionnaire has been administered, in ten Italian psychiatric care facilities, to a sample of 671 psychiatric patients (48.5% men; 51.5% women), aged between 18 and 26 years (mean age: 22.24).Results8.2% of the sample declared use of NPS at least once in a lifetime and 2.2% have assumed NPS in the last three months. The NPS more used were synthetic cannabinoids (4.5%), followed by methamphetamine (3.6%). The three psychiatric diagnosis with more frequent NPS consumption were bipolar disorder (23.1%), personality disorders (11.8%) and schizophrenia and related disorders (11.6%). Bipolar disorder was associated with NPS consumption (P < .001). Among the illicit drugs investigated, 31.4% of the sample was cannabis smoker and 10.7% cocaine user. Moreover, 70.6% of the sample declared alcohol use and 47.7% had binge drinking conducts. In univariate regression analysis, bipolar disorder was positive associated with binge drinking while obsessive compulsive disorder resulted negative associated.ConclusionsThe use of novel psychoactive substances in a young psychiatric population appears to be a frequent phenomenon, probably still underestimated. Bipolar disorder shows an association with NPS use. Therefore, careful and constant monitoring and accurate evaluations of possible clinical effects related to their use are necessary.Disclosure of interestThe authors have not supplied their declaration of competing interest.


2020 ◽  
Vol 10 (9) ◽  
pp. 606
Author(s):  
Liana Fattore ◽  
Matteo Marti ◽  
Rafaela Mostallino ◽  
Maria Paola Castelli

Sex and gender deeply affect the subjective effects and pharmaco-toxicological responses to drugs. Men are more likely than women to use almost all types of illicit drugs and to present to emergency departments for serious or fatal intoxications. However, women are just as likely as men to develop substance use disorders, and may be more susceptible to craving and relapse. Clinical and preclinical studies have shown important differences between males and females after administration of “classic” drugs of abuse (e.g., Δ9-tetrahydrocannabinol (THC), morphine, cocaine). This scenario has become enormously complicated in the last decade with the overbearing appearance of the new psychoactive substances (NPS) that have emerged as alternatives to regulated drugs. To date, more than 900 NPS have been identified, and can be catalogued in different pharmacological categories including synthetic cannabinoids, synthetic stimulants (cathinones and amphetamine-like), hallucinogenic phenethylamines, synthetic opioids (fentanyls and non-fentanyls), new benzodiazepines and dissociative anesthetics (i.e., methoxetamine and phencyclidine-derivatives). This work collects the little knowledge reached so far on the effects of NPS in male and female animal and human subjects, highlighting how much sex and gender differences in the effects of NPS has yet to be studied and understood.


Author(s):  
Anaam Ameen ◽  
Kelly Brown ◽  
Lynn Dennany

Abstract Synthetic Cannabinoids (SC) are amongst the most prevalent class of novel psychoactive substances (NPS) which have emerged. The increase in hospitalisation and fatalities as a result of the prevalence of these SC and their abuse, highlights the necessity for the rapid and reliable screening for the substance within toxicological samples. Being able to rapidly screen for these substances would aim to improve overdose triage and ultimately improve treatment administration. Not only this but it would have further advantages for in-field applications such as the identification of drivers under the influence. To this avail we investigate the ability of a simple electrochemical screening strategy for the detection of SC, BB-22 and its primary metabolite BB-22-3-Carboxyindole. Assessment of the feasibility of the strategy for implementation into toxicological sample analysis was performed through detection not only under ideal electrolyte conditions (down to 5 µM for BB-22 and 2 µM for its metabolite) but also within the complex biological matrix of human pooled serum (between 200 and 700 µM), a relevant matrix it would likely encounter if employed within this field.


Author(s):  
А.В. Анцыборов ◽  
О.В. Камплицкая ◽  
М.В. Овсянников ◽  
К.В. Стадник ◽  
Л.Ф. Панченко

С появлением на нелегальном рынке наркотиков новых психоактивных веществ, одно из первых в данном классе стали занимать синтетические каннабиноиды (СК). СК в основном распространяются через сеть Интернет, с помощью онлайн мессенджеров, и VPN-сетей. Токсическое влияние СК на организм человека оказывается достаточно мощным и нередко заканчивается летальным исходом. Однако аддиктивный потенциал СК достаточно высок, и нуждается в дальнейшем изучении, особенно с появлением новых классов СК. Разработка дифференциально-диагностических критериев и терапевтических подходов при лечении острых психотических состояний, вызванных употреблением СК, представляется актуальной задачей для практического здравоохранения. Цель: обзор накопленных научных данных о последствиях рекреационного употребления СК на организм человека. Материалы: при написании обзора использовали следующие репрезентативные базы данных: PubMed, Google Scholar, Embase, Cochrane, платформы SciFinder, и Scopus. Методы: в качестве поисковых запросов использовались следующие ключевые слова: Spice, K2, synthetic cannabis, new psychoactive sub-stances (NPS), adverse effects, cannabinoid’s receptor, psychosis due to the use NPS, fatalities. Реферируемые статьи были отфильтрованы по тезисам, с целью определения релевантности для настоящего обзора. With the emergence of novel psychoactive substances in the illegal drug market, synthetic cannabinoids (SCs) became one of the first in this class. SCs are mainly distributed through the Internet, by online messengers and VPN networks. The toxic effect of SCs on the human body is quite powerful and often results in death. The addictive potential of SCs is rather high and needs further study, especially with the emergence of new SC classes. Development of differential diagnostic criteria and therapeutic approaches in the treatment of acute psychotic conditions caused by the use of SCs is an urgent task for practical health care. Objective: to review scientific data on consequences of the recreational use of SCs in humans. Materials: data from six representative databases, PubMed, Google Scholar, Embase, Cochrane, the SciFinder platform, and Scopus, were used for this review. Methods: the following combinations and keywords were used as search queries: Spice, K2, synthetic cannabis, novel psychoactive substances (NPS), adverse effects, cannabinoid’s receptor, psychosis due to the use of NPS, fatalities. Peer-reviewed articles were filtered by abstracts to determine their relevance for the present review.


2020 ◽  
Vol 18 (10) ◽  
pp. 966-1051 ◽  
Author(s):  
Caroline Zangani ◽  
Fabrizio Schifano ◽  
Flavia Napoletano ◽  
Davide Arillotta ◽  
Liam Gilgar ◽  
...  

Background: A wide range of novel psychoactive substances (NPS) is regularly searched and discussed online by web-based drug enthusiasts (i.e. the e-psychonauts). Among NPS, the range of synthetic cannabinoids (SC; ‘Spice’) currently represents a challenge for governments and clinicians. Methods: Using a web crawler (i.e. the NPS.Finder®), the present study aimed at assessing psychonauts’ fora/platforms to better understand the online mentions of SC. Results: The open-web crawling/navigating software identified here some 1,103 synthetic cannabinoids. Of these, 863 molecules were not listed in either the international or the European NPS databases. Conclusions: A web crawling approach helped here in identifying a large range of unknown SC likely to possess a misuse potential. Most of these novel/emerging molecules are still relatively unknown. This is a reason for concern; each of these analogues potentially presents different toxicodynamic profiles and there is a lack of docking, preclinical, and clinical observations. Strengthening multidisciplinary collaboration between clinicians and bioinformatics may prove useful in better assessing SC-associated public health risks.


Author(s):  
Loretta T Ford ◽  
Jonathan D Berg

Introduction Novel psychotropic substances also known as legal highs are a major concern in UK prisons, fuelling violence and putting a strain on resources for inmates requiring medical treatment for adverse effects. We provide a clinical toxicology service including routine screening for novel psychoactive substances. In 2015, we were approached by Her Majesty Prison Service search dog training team to advise on which novel psychoactive substances to target, and again in 2016 to further provide analytical support to test five letters which the dogs positively identified for novel psychotropic substances during routine searches of prison mail rooms. Here we provide the first analytical confirmation that letters sent to inmates are being used to smuggle novel psychotropic substances into UK prisons. Results Novel psychotropic substances were detected on all five letters and these included the stimulants ethylphenidate, methiopropamine and methoxiphenidaine, the sedative etizolam and the third generation synthetic cannabinoids 5F-AKB-48, AB-FUBINACA, MDMB-CHMICA. Other compounds detected include the class A drug cocaine, class B drug methylphenidate and the cutting agents lignocaine, benzocaine and procaine. Conclusion Novel psychotropic substances smuggled into UK prisons is a major safety and security concern. By analytically confirming letters sent to inmates do contain novel psychotropic substances, we have produced categorical evidence to support anecdotal suggestions that novel psychotropic substances are entering UK prisons in this manner.


2017 ◽  
Vol 17 (3) ◽  
pp. 178-185 ◽  
Author(s):  
Raven Egheosa Owie ◽  
Paul Gosney ◽  
Andrew Roney ◽  
Aileen O’Brien

Purpose The purpose of this paper is to measure the level of experience and knowledge of novel psychoactive substances (NPS) amongst psychiatrists, asking them to rank NPS against other psychoactive substances in terms of concern and the role they believe NPS play in the diagnosis and management of psychiatric disorders. Design/methodology/approach An online survey was created and emailed to all 217 psychiatrists working for a large city Mental Health Trust. Findings In total, 108 of 217 psychiatrists responded to the survey. A majority of the respondents believed that their level of knowledge of NPS was inadequate and stated that they would like to receive more training. Half of them either named only one or no NPS that they had encountered within the last five years. There was a correlation between the experience of the respondent and the number of NPS that they could name. Practical implications Most of the respondents assessed their own knowledge of NPS as either poor or basic. Psychiatrists’ knowledge of NPS could be improved by having regular NPS-related training, by being sent regular updates on NPS and by including lectures in the Membership of the Royal College of Psychiatrists courses. Psychiatrists should also be encouraged to access online resources such as NEPTUNE and the European Monitoring Centre for Drugs and Drug Addiction. Originality/value This is the first survey of the UK psychiatrists of their knowledge and experience of NPS.


Sign in / Sign up

Export Citation Format

Share Document